MAZE
$48.03-1.40 (-2.83%)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Recent News
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum
Maze Therapeutics (MAZE), a clinical stage biopharmaceutical company focused on renal, cardiovascular and metabolic diseases, has recently drawn attention as investors consider its pipeline progress in relation to current trading levels. See our latest analysis for Maze Therapeutics. At a latest share price of $51.84, Maze Therapeutics has seen a 14.43% 7 day share price return and a 30.34% year to date share price return, while the 1 year total shareholder return is very large, indicating...
Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls
Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise spending and payments.